Vir Biotechnology, Inc. VIR
10.66
(0.06)
(0.56%)
as of 25 Sep
- Market cap
- $1.8B
- P/E
- 0.0×
Follow VIR
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (26.08%) | (47.69%) | (45.73%) | (49.06%) |
+8 more TTM periods Free account |
|
| (20.91%) | (37.95%) | (36.47%) | (39.69%) | ||
ROIC |
(39.10%) | (88.19%) | (101.09%) | (119.31%) | |
Return on Tangible Assets |
(47.56%) | (88.09%) | (91.84%) | (94.51%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.21) | (3.05) | (2.86) | (3.29) | |
Free Cash Flow |
(203.67) | (449.67) | (396.36) | (457.20) | |
Capital Expenditures |
(1.16) | (3.62) | (4.58) | (3.66) | |
Piotroski F-Score |
4.00 | 3.00 | 3.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(13.35%) | (34.55%) | (31.74%) | (34.76%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.10 | 0.10 | |
Inventory Turnover |
— | — | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 5,039.57 | 3,404.84 | |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
159.62% | 681.34% | 665.10% | 2,809.61% | |
Selling, General and Administrative Expense of Revenue |
32.77% | 139.66% | 134.30% | 564.41% | |
Share Based Compensation of Revenue |
15.51% | 71.91% | 71.58% | 318.55% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.80 | 1.01 | 0.89 | 0.91 | |
Depreciation/Fixed assets |
0.30 | 0.33 | 0.38 | 0.37 | |
Capex/Depreciation |
(0.08) | (0.21) | (0.22) | (0.17) | |
Revenue per Share |
1.81 | 0.44 | 0.49 | 0.12 | |
Operating CF per Share |
(1.21) | (3.03) | (2.83) | (3.26) | |
Capex per Share |
(0.01) | (0.02) | (0.03) | (0.03) | |
Capex to Sales |
0.00 | 0.06 | 0.07 | 0.22 | |
Net Profit Margin |
(83.00%) | (675.96%) | (638.87%) | (2,963.54%) |
Columns are period end dates